Definium Therapeutics Inc... (DFTX)
Definium Therapeutics Inc. (DFTX) Stock Price, Analysis & Data
| Бид | 33.63 |
| Рыночная капитализация | 6.16B |
| Выручка (TTM) | n/a |
| Чистая прибыль (TTM) | -353.78M |
| Бета | 2.26 |
| EPS (TTM) | -3.4 |
| P/E (TTM) | n/a |
| Прогнозный P/E | -24.43 |
| P/B (TTM) | 6.70 |
| P/S (TTM) | n/a |
| Earnings Date | n/a |
| Аск | 57.7 |
| Объём торгов | 1,746,550 |
| Ср. объём (20д) | 3,028,916 |
| Открытие | 47.00 |
| Пред. закрытие | 46.18 |
| Диапазон дня | 44.59 - 47.29 |
| Диапазон за 52 недели | 8.70 - 49.70 |
| Аналитики | n/a |
| Целевая цена | n/a |
| Дивиденды | n/a |
| Дата отсечки | n/a |
О компании DFTX
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum d...
Финансовые результаты
В 2025 году выручка Definium Therapeutics составила 0 — это рост на undefined% к прошлогодним 0. Прибыль составила -183.79M — это рост на 69.12%.
Финансовая отчётностьСюрприз в отчёте
6 дней назад · Simply Wall St.
Definium Therapeutics (DFTX) Voyage Data Puts Valuation Back In FocusDefinium Therapeutics (DFTX) is back in focus after reporting positive topline results from its Phase 3 Voyage study of DT120 ODT in generalized anxiety disorder. This event has quickly refocused atte...
1 неделю назад · Simply Wall St.
Definium Therapeutics (DFTX) Hits Phase 3 GAD Goals For DT120 ODTDefinium Therapeutics (NasdaqGS: DFTX) reported positive topline data from its pivotal Phase 3 Voyage trial of DT120 ODT in adults with generalized anxiety disorder. The study met all primary and key ...